Positive Phase II results for investigational selective Janus kinase type 1 (JAK1) inhibitor (SHR0302) in ulcerative colitis

In the double-blind AMBER2 study (n=164 adults with moderate to severe UC), a Clinical Response per the 9-point Mayo Score at week 8 (primary endpoint) was achieved by 43.9-46.3% across all doses compared to 26.8% with placebo.

Source:

Biospace Inc.